Meeting
2019 Genitourinary Cancers Symposium
Effect of immunotherapy (IO) on primary renal tumor in metastatic renal cell cancer (mRCC).
Authors
Antoine Jamet
Institut Gustave Roussy, Villejuif, France
Antoine Jamet , Caroline Caramella , Annalisa Guida , Julia Arfi-Rouche , Zahira Merabet , Emeline Colomba , Bernard Escudier , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 649)
DOI
10.1200/JCO.2019.37.7_suppl.649
Abstract #
649
Poster Bd #
J2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immunotherapy: A systematic review and meta-analysis.
First Author: Fengnian Zhao
Poster
2020 Genitourinary Cancers Symposium
Association of serum iron and response to immune checkpoint inhibitors (ICIs) in metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Nityam Rathi
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of cytoreductive nephrectomy on the efficacy of immunotherapy in metastatic renal cell carcinoma by decreasing IL-6 to modulate tumor-associated macrophage and myeloid-derived suppressor cell.
First Author: Jee Soo Park
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
First Author: Michael Bitzer